Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials [Forbes]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Forbes
pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly's Mounjaro and Novo Nordisk's Ozempic. Key Facts Orforglipron is the first GLP-1 drug in pill form to successfully complete a phase III trial, which is a study that tests the safety and efficacy of a new treatment. The trial compared the effectiveness of orforglipron in adults with type 2 diabetes and blood sugar levels not within the recommended range to a placebo of diet and exercise alone. Study results showed success in lowering A1C, or average blood sugar levels, as well as significant weight loss, with participants on the highest dosage losing 16 pounds on average during just the 40-week trial–similar results to the average weight lost on Ozempic over the same timeframe and slightly less than Mounjaro Once a phase III trial is complete, a pharmaceutical company can request approval from the Food and Drug Administration. Eli Lilly's stock price was up
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss [Yahoo! Finance]Yahoo! Finance
- SA analyst upgrades/downgrades: NVO, INTC, ADBE, WDAY [Seeking Alpha]Seeking Alpha
- EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above [Yahoo! Finance Canada]Yahoo! Finance Canada
- High-end Swiss chocolatier Läderach rules out U.S. production despite tariff shock [CNBC]CNBC
- Weight-loss drug developers line up to tap lucrative market as competition heats up [BNN Bloomberg (Canada)]BNN Bloomberg
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website